Navigation Links
Cethrin in Medical News

Alseres Shares Begin Trading on the Pink Sheets OTC Market

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice - 508-497-2360 ext. 226 Alseres Pharmaceu...

Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology

...ed in December 2006 and amended in March 2007 (the cethrin License) was further amended. The Amendment repla...nd performance-related milestones contained in the cethrin License with a formula-based approach to sharing a...nt for the compounds and technology covered by the cethrin License. In the event that the Company fails to s...

Alseres Pharmaceuticals, Inc. Receives Notice of De-Listing of Its Securities for Failure to Regain Compliance with Continued Listing Requirements

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice - 508-497-2360 ext. 226 Alseres Pharmaceu...

Alseres Pharmaceuticals, Inc. Announces $200,000 Financing

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice -- 508-497-2360 ext. 226 Alseres Pharma...

Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia Alseres Pharmaceuticals, Inc 50...

Alseres Pharmaceuticals, Inc. Announces $1 Million Financing

...ing the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia -- 508-497-2360 ext. 224 Alseres Pha...

Alseres Pharmaceuticals, Inc. To Host Third Quarter 2008 Conference Call

...providing the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres Pharmaceuticals,...

Alseres Pharmaceuticals, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference

...yndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres Pharmaceuticals...

Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results

...ful, this trial will provide us with evidence that cethrin is more effective than a placebo in treating acute...ur preliminary planning for the Phase IIb trial of cethrin called for us to enroll up to 100 subjects in 80 s...ropriate sites and investigators for the Phase IIb cethrin study expected to commence in the first quarter of...

Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call

...providing the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres Pharmaceuticals...
Cethrin in Medical Technology

Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons

Company Announces Extension of Phase I/IIa Trial to 9 mg Dosage Level HOPKINTON, Mass., April 16, 2007 /PRNewswire-FirstCall/ -- Boston Life Sciences announced today that clinical data on its lead nerve repair therapy, Cethrin(R), were presented in the Neurotrauma and Critical Care Scientific Sess...

Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres ...

Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury

... Analysis of the data by dose group indicates that cethrin doses of 1 and 3 mg appear to be the most benefici... ) "The safety and efficacy observations of the cethrin trial continue to be encouraging. Many patients ha...orward with its previously announced plans for the cethrin Phase IIb trial in acute spinal cord injury in the...

Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates

...eres may exercise an option to amend the Company's cethrin License Agreement. (Logo: http://www.newscom.co...ard for Alseres in realizing the full value of our cethrin spinal cord program and our Rho inhibitor technolo...cts in a Phase I/IIa clinical trial indicated that cethrin was safe and well tolerated. The overall populatio...

Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program

...rmation in this press release as of this date and assumes no obligations to update the information in this press release. Alseres is a trademark and cethrin and ALTROPANE are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia -- 508-497-2360 ext 224 scorreia@alseres.com or ...

Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008

...ark Hurtt, Chief Medical Officer, will discuss the cethrin development program as a member of an expert panel...ion, Dr. Hurtt will present interim results of the cethrin Phase I/IIa clinical trial in acute spinal cord in...acy results from the first 37 patients in Alseres' cethrin Phase I/IIa study. The data indicated that...

Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury

...ed enrollment in the Phase I/IIa clinical trial of cethrin in acute spinal cord injury (SCI). A total of 48 s...iously announced plans for the placebo-controlled, cethrin Phase IIb trial in acute spinal cord injury at sit...rope and other countries in 2008. "We believe that cethrin continues to be the most advanced drug candidate i...

Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial

... DSMB's recommendation is an important step in the cethrin clinical plan," commented Dr. Mark Hurtt, Alseres'...understanding of the encouraging efficacy data for cethrin at lower doses, and provide additional safety data...ient enrollment in early 2008." About Cethrin(R) cethrin is a recombinant protein drug intended to facilita...
Cethrin in Biological Technology

Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. http://www.alseres.com/ Contact: Kenneth L. Rice 508...

Alseres Pharmaceuticals, Inc. Announces $1 Million Financing

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice -- 508-497-2360 ext. 226 Alseres Pharma...

Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results

...8, in Washington, DC by Dr. Michael Fehlings, principal Investigator of the cethrin Phase I/IIa trial. -- We are pursuing development and commercialization p... no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. ...

Alseres Pharmaceuticals, Inc. Raises $5 Million

...rmation in this press release as of this date and assumes no obligations to update the information in this press release. Alseres is a trademark and cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia -- 508-497-2360 ext. 224 Alseres Pharmaceut...

Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights

...d Injury on the first 37 subjects treated with cethrin at doses up to 6 mg. The data indicated that cethrin was safe and well tolerated. The overall population of patients treated with cethrin demonstrated an improvement in their impairmen...

Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference

...tegies, plans or prospects regarding the future, including the Company's clinical development and trials for CETHRIN, the prospects of FDA approval of cethrin and the commercialization, including partnering opportunities, of CETHRIN. Forward- looking statements can be identified by terminology such as "antic...

Alseres Pharmaceuticals, Inc. to Present at Windhover's Therapeutic Area Partnerships Conference

...cted in several important initiatives. Cethrin(R) is a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. cethrin has demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the t...

Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting

...cted in several important initiatives. Cethrin(R) is a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. cethrin has demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the t...
Other Tags
(Date:12/24/2014)... 24, 2014 (HealthDay News) -- The holidays can be a ... off by certain foods and drinks. "This is the ... trigger attacks of migraine," Dr. David Dodick, chair of the ... foundation. "It,s important to think through food and beverage ... attack," added Dodick, a professor of neurology at the Mayo ...
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- A new, injectable ... and Drug Administration. The agency on Tuesday approved ... those who are overweight and have at least one ... 2 diabetes or high cholesterol. Patients taking the ... low-calorie diet and exercise regularly, the FDA noted. ...
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- Researchers say they ... that develop into eggs and sperm. While this ... is the first time that these types of cells ... efficiently using human stem cells, according to the team ... creation of primordial germ cells is one of the ...
(Date:12/24/2014)... lab technician with the U.S. Centers for Disease Control ... virus in an agency laboratory in Atlanta earlier this ... workers are being checked for possible exposure, CDC officials ... Monday when CDC scientists doing research on Ebola mistakenly ... another CDC lab in the same building, the ...
(Date:12/24/2014)... Gluten, a protein found predominately in ... an intolerance to gluten, causing side effects that can ... joint pain and fatigue. For this reason, Diet Doc ... deliver safe and fast weight loss while teaching patients ... allergy reaction. These gluten free diet plans combine the ...
Breaking Medicine News(10 mins):Health News:Expert Offers Tips for Preventing Holiday Migraines 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:CDC Monitors Lab Worker for Possible Ebola Exposure 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ... Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter security ... 3.6% from 2014 to 2019. Although the U.S. market ... Canada is expected to grow at a ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 ... than the iPhone 5S, Samsung introduces for the ... The Galaxy S5 home button presents ...
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
Other Contents